News and Trends 18 Jan 2024 2024 J.P. Morgan Healthcare Conference: key takeaways from the largest biotech gathering of the year …rare disorders. Delving into CNS, Paul Little, chief executive officer (CEO) of the clinical biotech Vesper Bio ApS, said: “CNS is in vogue and it is not just about new… January 18, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Sponsored by Collaborative Drug Discovery Inc. 25 Feb 2025 How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases …system Libra’s pipeline targets mechanisms that can mitigate protein pathology associated with CNS degenerative disorders. The lead program is focused on identifying small molecule activators of TRPML1 for the treatment… February 25, 2025 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 PsychoGenics launches eCube AI platform for drug discovery …multiple targets. Similar to the company’s AI-enabled, behavior-based platform, SmartCube, eCube harnesses machine learning to identify central nervous system (CNS) penetrant compounds and predict their therapeutic applications for neuropsychiatric disorders… April 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 31 Jan 2017 Biologicals on the Brain: Biotech in Neurodegenerative Disease …CNS diseases. However, in the last few years we have seen a resurgence in interest in tackling this issue with various different approaches,” Joy Zuchero, a scientist at the US-based… January 31, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain …Gate launches to develop CNS treatments Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate, a… September 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug …novel routes of drug delivery. Multiple indications “I am thrilled to see the company advancing foralumab into another promising central nervous system (CNS) -related therapeutic area with high unmet need,”… October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2025 3 promising biotech approaches to treat Hunter syndrome, a rare genetic disorder …been shown to improve somatic signs and symptoms of Hunter syndrome, the drug does not cross the blood-brain barrier, meaning it has limited action on the central nervous system (CNS)… February 20, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 5 Nov 2024 From consumer health to pure biopharma: Inside Sanofi’s strategic shift …use of MeiraGTx’s riboswitch gene regulation technology in areas such as immunology and inflammation, central nervous system (CNS) targets, GLP-1 and other gut peptides for metabolic diseases, as well as… November 5, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 5 Dec 2024 The biggest private biotech investments in November 2024 …of $565 million from eight funding rounds. Meanwhile, CNS and genetic disorder players had the joint second-most amount of rounds with three each, but CNS companies brought in much more… December 5, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 26 Oct 2022 Neuraxpharm to commercialize device giving early warning of epileptic seizures A wearable medical device that can give an early warning of an epileptic seizure has been developed by medical device startup, mjn-neuro. Central nervous system (CNS) specialist Neuraxpharm Group entered… October 26, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2020 Spanish Neurology Biotech Launches with €7.6M Series A Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life… May 29, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 17 Mar 2025 How biotechs are using AI to rescue failed drugs …developers for various other reasons. The company has a particular focus on repurposing drugs for neuroscience. Developing drugs for central nervous system (CNS) indications generally takes longer and has historically… March 17, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email